PMID- 16571285
OWN - NLM
STAT- MEDLINE
DCOM- 20061006
LR  - 20221207
IS  - 1672-0415 (Print)
IS  - 1672-0415 (Linking)
VI  - 12
IP  - 1
DP  - 2006 Mar
TI  - Improvement of quality of life with Shenfu injection in non small cell lung 
      cancer patients treated with gemcitabine plus cisplatin regimen.
PG  - 50-4
AB  - OBJECTIVE: To observe the effect of Shenfu injection (SFI) in treating non small 
      cell lung cancer (NSCLC) patients on quality of life with gemcitabine (GEM) plus 
      cisplatin (GP) regimen. METHODS: Thirty-four patients were ready to receive GP 
      regimen chemotherapy for treating NSCLC disease, according to lot-drawing, they 
      were divided into SFI pre-treatment group (18 cases) and SFI post-treatment group 
      (16 cases). SFI pre-treatment group: During the first treatment course, 
      chemotherapy was begun with SFI 60 ml, intravenous dripping on the 3rd day, once 
      daily, consecutively for 10 days; on the 1st day, GP regimen (GEM 1250 mg/m(2), 
      intravenous dripping, on the 1st and 8th day; cisplatin 70 mg/m(2) on the 2nd 
      day; 21 days as one cycle) was carried out; in the second treatment course GP 
      regimen was merely given to serve as the self-control. SFI post-treatment group: 
      the medicament sequence order was reversed from that of pre-treatment group. 
      Using dual international quality of life (QOL) scores, the effect of SFI on the 
      patients' QOL was observed through randomized self pre- and post-crossover 
      control. RESULTS: The QOL in the 34 patients after being treated by SFI in 
      combination with GP chemotherapy regimen in one group, and GP chemotherapy 
      regimen alone in the other, was improved in different degrees, with significant 
      difference (P < 0.01); comparison of SFI combined with GP chemotherapy regimen 
      with GP chemotherapy alone showed that QOL in patients was significantly 
      different (P < 0.01). CONCLUSION: SFI could improve QOL in patients with NSCLC 
      who were treated with GP regimen.
FAU - Wu, Wan-yin
AU  - Wu WY
AD  - Department of Cancer, Guangdong Provincial Traditional Chinese Medicine Hospital, 
      Guangzhou 510370. wwanyin@126.com
FAU - Long, Shun-qin
AU  - Long SQ
FAU - Zhang, Hai-bo
AU  - Zhang HB
FAU - Chai, Xiao-shu
AU  - Chai XS
FAU - Deng, Hong
AU  - Deng H
FAU - Xue, Xiao-guang
AU  - Xue XG
FAU - Wang, Bin
AU  - Wang B
FAU - Luo, Hai-ying
AU  - Luo HY
FAU - Liu, Wei-sheng
AU  - Liu WS
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Chin J Integr Med
JT  - Chinese journal of integrative medicine
JID - 101181180
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Shen-Fu)
RN  - 0W860991D6 (Deoxycytidine)
RN  - Q20Q21Q62J (Cisplatin)
RN  - 0 (Gemcitabine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - Cisplatin/administration & dosage/adverse effects
MH  - Cross-Over Studies
MH  - Deoxycytidine/administration & dosage/adverse effects/analogs & derivatives
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - *Quality of Life
MH  - Gemcitabine
EDAT- 2006/03/31 09:00
MHDA- 2006/10/07 09:00
CRDT- 2006/03/31 09:00
PHST- 2006/03/31 09:00 [pubmed]
PHST- 2006/10/07 09:00 [medline]
PHST- 2006/03/31 09:00 [entrez]
AID - 10.1007/BF02857431 [doi]
PST - ppublish
SO  - Chin J Integr Med. 2006 Mar;12(1):50-4. doi: 10.1007/BF02857431.